Physician profile
Peter D Murr
NPI 1306190665
$2,809.02
in general payments reported to CMS, 2019-2025
21 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $240 · 2021: $116 · 2022: $157 · 2023: $764 · 2024: $664 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,998 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,997.93 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,173.12 | 2019-2025 | Clareon, Centurion, Tryptyr |
| Bausch & Lomb Americas INC. | $338.89 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Astellas Pharma US INC | $267.02 | 2023 | Izervay |
| Allergan, INC. | $236.94 | 2019-2021 | |
| Dompe US, INC. | $135.97 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $124.75 | 2019-2023 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $83.34 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $80.24 | 2019-2023 | |
| Oyster Point Pharma, INC. | $57.62 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $48.02 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $45.53 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $38.62 | 2025 | Tecnis Iol, Catalys System, Tecnis Iol |
| Eyepoint US, INC. | $32.81 | 2019-2020 | |
| Biotissue Holdings INC. | $32.39 | 2022 | |
| Sight Sciences, INC. | $26.41 | 2025 | Omni Surgical System, Sion Surgical Instrument |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $19.69 | 2025 | Photrexa Viscous and Photrexa |
| Harrow Eye, LLC | $14.90 | 2024 | Iheezo |
| Shire North American Group INC | $14.57 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.29 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.15 | 2019 | |
| Abbvie INC. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Murr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.